Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the sixteen ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, thirteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $115.2143.
A number of research firms have recently commented on PTGX. Citigroup restated an “outperform” rating on shares of Protagonist Therapeutics in a research report on Wednesday, May 6th. Wolfe Research began coverage on Protagonist Therapeutics in a research report on Thursday, May 21st. They issued an “outperform” rating and a $135.00 price objective for the company. Jefferies Financial Group restated a “buy” rating and issued a $121.00 price objective on shares of Protagonist Therapeutics in a research report on Wednesday, March 18th. Wall Street Zen cut Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, JPMorgan Chase & Co. boosted their price objective on Protagonist Therapeutics from $95.00 to $106.00 and gave the company an “overweight” rating in a research report on Thursday, March 19th.
Read Our Latest Report on PTGX
Insiders Place Their Bets
Institutional Trading of Protagonist Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in PTGX. Farther Finance Advisors LLC increased its position in shares of Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after purchasing an additional 156 shares in the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of Protagonist Therapeutics by 1.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 13,393 shares of the company’s stock worth $1,170,000 after purchasing an additional 193 shares in the last quarter. Maryland State Retirement & Pension System increased its position in shares of Protagonist Therapeutics by 2.3% during the fourth quarter. Maryland State Retirement & Pension System now owns 8,603 shares of the company’s stock worth $751,000 after purchasing an additional 196 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Protagonist Therapeutics by 7.8% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,760 shares of the company’s stock worth $291,000 after purchasing an additional 200 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its position in shares of Protagonist Therapeutics by 8.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,959 shares of the company’s stock worth $258,000 after purchasing an additional 221 shares in the last quarter. 98.63% of the stock is currently owned by hedge funds and other institutional investors.
Protagonist Therapeutics Trading Up 0.8%
Shares of PTGX stock opened at $122.58 on Wednesday. The stock has a 50 day moving average of $105.08 and a 200 day moving average of $95.67. The stock has a market cap of $7.88 billion, a P/E ratio of -67.72 and a beta of 1.85. Protagonist Therapeutics has a twelve month low of $49.38 and a twelve month high of $126.59.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.55. The company had revenue of $56.37 million during the quarter, compared to analysts’ expectations of $11.70 million. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%. On average, research analysts predict that Protagonist Therapeutics will post 2.93 earnings per share for the current fiscal year.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.
Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.
Read More
- Five stocks we like better than Protagonist Therapeutics
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
